Evidence map›Paper›PMID 31601221›Full record

ArticleAnnals of clinical microbiology and antimicrobials2019

Determining the clinical significance of co-colonization of vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in the intestinal tracts of patients in intensive care units: a case-control study.

Young Kyung Yoon, Min Jung Lee, Yongguk Ju, Sung Eun Lee, Kyung Sook Yang, Jang Wook Sohn, Min Ja Kim

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Associations Between Candida andMicroorganisms · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Total Synthesis of Pargamicin A.Organic letters · 2022
    Article
  9. Article
  10. Prevalence and Antibiotic Susceptibility Trends of SelectedAntibiotics (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Young Kyung YoonDivision of Infectious Diseases, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Inchon-ro 73, Seongbuk-gu, Seoul, 02841, Republic of Korea.
Min Jung LeeInfection Control Unit, Korea University Medical Center, Seoul, Republic of Korea.
Yongguk JuInstitute of Emerging Infectious Diseases, Korea University College of Medicine, Seoul, Republic of Korea.
Sung Eun LeeInfection Control Unit, Korea University Medical Center, Seoul, Republic of Korea.
Kyung Sook YangDepartment of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea.
Jang Wook SohnDivision of Infectious Diseases, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Inchon-ro 73, Seongbuk-gu, Seoul, 02841, Republic of Korea.
Min Ja KimDivision of Infectious Diseases, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Inchon-ro 73, Seongbuk-gu, Seoul, 02841, Republic of Korea. macropha@korea.ac.kr.ORCID http://orcid.org/0000-0002-2125-7521
Korea University · KRKorea University Medical Center · KR

Funding

Korean Society for Antimicrobial Therapy NAMinistry of Health & Welfare, Republic of Korea HI16C1048
6 · The paper itself

Abstract

backgroundThe emergence of vancomycin-resistant Staphylococcus aureus (VRSA) has become a global concern for public health. The proximity of vancomycin-resistant enterococcus (VRE) and methicillin-resistant S. aureus (MRSA) is considered to be one of the foremost risk factors for the development of VRSA. This study aimed to determine the incidence, risk factors, and clinical outcomes of intestinal co-colonization with VRE and MRSA.

methodsA case-control study was conducted in 52-bed intensive care units (ICUs) of a university-affiliated hospital from September 2012 to October 2017. Active surveillance using rectal cultures for VRE were conducted at ICU admission and on a weekly basis. Weekly surveillance cultures for detection of rectal MRSA were also conducted in patients with VRE carriage. Patients with intestinal co-colonization of VRE and MRSA were compared with randomly selected control patients with VRE colonization alone (1:1). Vancomycin minimum inhibitory concentrations (MICs) for MRSA isolates were determined by the Etest.

resultsOf the 4679 consecutive patients, 195 cases and 924 controls were detected. The median monthly incidence and duration of intestinal co-colonization with VRE and MRSA were 2.3/1000 patient-days and 7 days, respectively. The frequency of both MRSA infections and mortality attributable to MRSA were higher in the case group than in the control group: 56.9% vs. 44.1% (P = 0.011) and 8.2% vs. 1.0% (P = 0.002), respectively. Independent risk factors for intestinal co-colonization were enteral tube feeding (odds ratio [OR], 2.09; 95% confidence interval [CI] 1.32-3.32), metabolic diseases (OR, 1.75; 95% CI 1.05-2.93), male gender (OR, 1.62; 95% CI 1.06-2.50), and Charlson comorbidity index < 3 (OR, 3.61; 95% CI 1.88-6.94). All MRSA isolates from case patients were susceptible to vancomycin (MIC ≤ 2 mg/L).

conclusionsOur study indicates that intestinal co-colonization of VRE and MRSA occurs commonly among patients in the ICU with MRSA endemicity, which might be associated with poor clinical outcomes.

Indexed as

AgedAnti-Bacterial AgentsCarrier StateCase-Control StudiesCoinfectionFemaleGastrointestinal TractGram-Positive Bacterial InfectionsHospitals, UniversityHumansIncidenceIntensive Care UnitsMaleMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsMiddle AgedAnti-Bacterial AgentsActive surveillanceInfection controlMethicillin-resistant Staphylococcus aureusRisk factorVancomycin-resistant enterococci

Identifiers

PMID31601221
PMCPMC6785887
OpenAlexW2979712788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.